Melrilimab
Based on 1 Customer Validation
Melrilimab (GSK 3772847; CNTO-7160) is a humanized IgG2σ monoclonal antibody that targets the IL-33 receptor ST2 and blocks the IL-33/ST2 signaling pathway by binding to the ST2 protein. Melrilimab is applicable to research related to asthma and atopic dermatitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.07%
- CAS No.: 2222865-46-3
- Masse moléculaire:145.2 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG2 kappa
Human
|
ST2 |
Melrilimab effectively binds to its target in vivo, inhibits serum free sST2 and accumulates total sST2, but fails to significantly improve the clinical symptoms of asthma and atopic dermatitis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2222865-46-3
-
Appearance Liquid
-
Masse moléculaire 145.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Melrilimab]
-
Synonyms
GSK 3772847; CNTO-7160
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Sheng F, et al. IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential. Frontiers in immunology. 2025;16:1533335. [Content Brief]
[2]. Timotievich ED, et al. Role of Cytokines IL-25, IL-33, and TSLP in the Respiratory Tract Inflammation: Therapeutic Perspectives. Biochemistry. Biokhimiia. 2026 Jan;91(1):17-38. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz